Show simple item record

dc.contributor.authorINANC, S
dc.contributor.authorDINCOL, K
dc.contributor.authorOZTURK, N
dc.contributor.authorAYKAN, F
dc.contributor.authorTOPUZ, E
dc.contributor.authorAYDINER, A
dc.contributor.authorONAT, H
dc.date.accessioned2021-03-06T10:51:50Z
dc.date.available2021-03-06T10:51:50Z
dc.date.issued1993
dc.identifier.citationAYDINER A., ONAT H., OZTURK N., AYKAN F., INANC S., TOPUZ E., DINCOL K., "THE EFFICACY OF A 5-DRUG ANTIEMETIC COMBINATION DURING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN OR CYCLOPHOSPHAMIDE DOXORUBICIN", JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, cilt.8, ss.126-131, 1993
dc.identifier.issn0885-3924
dc.identifier.othervv_1032021
dc.identifier.otherav_ec5bf2d6-9787-4496-96a2-2628f7373e46
dc.identifier.urihttp://hdl.handle.net/20.500.12627/155189
dc.identifier.urihttps://doi.org/10.1016/0885-3924(93)90140-q
dc.description.abstractA five-drug combination, including metoclopramide, thiethylperazine, diphenhydramine, dexamethasone, and diazepam, was given to 32 patients during three consecutive treatments with chemotherapy. Eighteen patients (group A) were treated with a cisplatin-containing regimen, and 14 patients (group B) were treated with a cyclophosphamide- and doxorubicin-containing chemotherapy. In group A, complete responses were lower on the first day than on the second and third days (P < 0.015 and P < 0.041, respectively), during the first and second courses. The five-drug antiemetic regimen seems safe and effective. These results show that clinical trials that evaluate antiemetic efficacy in cisplatin-containing chemotherapy regimens should evaluate at least two consecutive courses.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectTıp
dc.subjectKLİNİK NEUROLOJİ
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectSağlık Bilimleri
dc.subjectAile Hekimliği
dc.subjectNöroloji
dc.subjectSAĞLIK BAKIM BİLİMLERİ VE HİZMETLERİ
dc.titleTHE EFFICACY OF A 5-DRUG ANTIEMETIC COMBINATION DURING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN OR CYCLOPHOSPHAMIDE DOXORUBICIN
dc.typeMakale
dc.relation.journalJOURNAL OF PAIN AND SYMPTOM MANAGEMENT
dc.contributor.department, ,
dc.identifier.volume8
dc.identifier.issue3
dc.identifier.startpage126
dc.identifier.endpage131
dc.contributor.firstauthorID114274


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record